Regeneron, Sanofi Say Eosinophilic Esophagitis Drug Recommended for Children in EU
Express News | Dupixent® (Dupilumab) Recommended for EU Approval by the Chmp to Treat Eosinophilic Esophagitis (Eoe) in Children as Young as 1 Year Old
The Best Biotech Plays Outside the GLP-1 Weight-loss Market
Unmissable investment strategy! The Federal Reserve officially enters a new era of interest rate cuts, these 6 industries have the most profitable potential.
Prepare yourself for the interest rate cut cycle.
Regeneron Pharma Price Target Maintained With a $1282.00/Share by RBC Capital
RBC Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,282
RBC Capital analyst Brian Abrahams maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,282.According to TipRanks data, the analyst has a success
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,300
BMO Capital analyst Evan Seigerman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and maintains the target price at $1,300.According to TipRanks data, the analyst has a success
BofA Securities Initiates Regeneron Pharmaceuticals(REGN.US) With Sell Rating, Announces Target Price $805
BofA Securities analyst Alec Stranahan initiates coverage on $Regeneron Pharmaceuticals(REGN.US)$ with a sell rating, and sets the target price at $805.According to TipRanks data, the analyst has a
Cantor Fitzgerald Reiterates Neutral on Regeneron Pharmaceuticals, Maintains $1015 Price Target
Regeneron Pharmaceuticals Analyst Ratings
Don't just focus on the polls! The trend of the US stock market is the compass for the US presidential election. Here is an investment guide for you to check out.
Analysts have found that since 1984, as long as the S&P 500 index rises accumulatively between August and October, the ruling party will win the election; on the contrary, if the S&P 500 index drops during this period, the challenger will win.
Cramer's Week Ahead: Fed Rate Decision, Earnings From Darden and Cracker Barrel
Regeneron, Sanofi Get FDA Approval for Upper Airway Disease Treatment
Regeneron Pharmaceuticals And Sanofi Announce FDA Approval For Dupixent In The U.S. As First And Only Treatment For Adolescents With Chronic Rhinosinusitis With Nasal Polyps
Express News | Dupixent® (Dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Dupixent (Dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
The first debate effect is evident! 'Harris trade' goes up, 'Trump trade' goes down. How should we trade if the situation changes?
CITIC Securities reminds that previous US elections have often been accompanied by frequent changes in the situation, such as the "email gate" incident involving Hillary in 2016, which led to a significant change in the polls. Therefore, there is still the possibility of unexpected changes in the subsequent election situation.
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
BMO Capital analyst Evan Seigerman maintains $Regeneron Pharmaceuticals(REGN.US)$ with a buy rating, and adjusts the target price from $1,082 to $1,300.According to TipRanks data, the analyst has a